MedPath

Pilot study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients with Poor Risk Myelodysplastic Syndrome and Acute Myeloid Leukaemia utilising conditioning with Fludarabine, Busulphan and Thymoglobuline

Phase 1
Conditions
Myelodysplastic SyndromeAcute myeloid leukaemia
MedDRA version: 8.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromes
Registration Number
EUCTR2006-004452-20-GB
Lead Sponsor
King's College Hospital NHS Foundation Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1.Availability of a HLA compatible sibling donor
2.Age >18 years
3.Myelodysplastic Syndromes with IPSS Intermediate-2 or High.
4.Poor risk acute myeloid leukaemia, de novo or transformed from MDS
5.Ineligibility for standard conditioning allograft due to age or co-existing morbidities

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1.Cardiac insufficiency requiring treatment or symptomatic coronary artery disease.
2.Hepatic disease, with AST > 2 times normal.
3.Severe hypoxaemia, pO2 < 70 mm Hg, with decreased DLCO < 70% of predicted; or mild hypoxemia, pO2 < 80 mm Hg with severely decreased DLCO < 60% of predicted.
4.Impaired renal function (creatinine > 2 times upper limit of normal or creatinine clearance < 50% for age, gender, weight).
5.Patients who have received previous treatment with Thymoglobuline
6.HIV-positive patients.
7.Female patients who are pregnant or breast feeding due to risks to foetus from conditioning regimen and potential risks to nursing infants.
8.Life expectancy severely limited by diseases other than MDS or MPD.
9.Serious concurrent untreated infection
10.Patients with limited life expectancy for other reasons
11.Serious psychiatric/ psychological disorders
12.Absence of /inability to provide informed consent

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath